Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Curis Lifesciences Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Curis Lifesciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Curis Lifesciences - Trading Window

    17 Nov 2025, 5:56PM Curis Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulation
  • Curis Lifesciences Ltd. debuts with 14.14% premium at Rs 146.10

    14 Nov 2025, 10:00AM Curis Lifesciences Ltd. makes a strong debut on the bourses with scrip got listed at Rs 146.10 on the Bombay Stock Exchange, a 14.14 per cent premium
  • Curis Lifesciences announces launch of initial public offering

    31 Oct 2025, 2:11PM Curis Lifesciences Ltd. has announced public offering of 2150000 shares at a price of Rs 10.00 each for Cash at a Premium of Rs 118.00 per share. The

Key fundamentals

Evaluate the intrinsic value of Curis Lifesciences Ltd stock 

Name March-25 March-24
Assets 31.8451 22.9618
Liabilities 31.8451 22.9618
Equity 5.9344 0.5
Gross Profit 9.5373 8.3876
Net Profit 6.1051 4.867
Cash From Operating Activities -1.7625 0.28
NPM(%) 12.42 13.68
Revenue 49.1323 35.5557
Expenses 39.595 27.1681
ROE(%) 28.73 22.9

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Curis Lifesciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 780.40 -0.84 0.00 0.00 301.39 0.64
Lotus Eye Hospital and Institute Ltd 105.00 -0.57 328.13 0.00 3.55 0.00
Vaishali Pharma Ltd 9.11 -3.80 0.00 0.00 3.13 0.00
Astec Lifesciences Ltd 890.00 7.36 0.00 0.00 -604.77 0.00

Company Info

Our Company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Loreto Pharmaceutacals", pursuant to a deed of partnership dated June 2, 2010. Thereafter " M/s Loreto Pharmaceuticals" was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of "Curis Lifesciences Private Limited" and received a certificate of incorporation datedMarch 23, 2016 issued by Assistant Registrar of Companies, Gujarat. Subsequently, our Company was converted into a public limited company and the name of our Company was changed from "Curis Lifesciences Private Limited" to "Curis Lifesciences Limited" vide Special Resolution dated May 6, 2024, the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion, bearing Corporate Identification Number U24230GJ2016PLC086559, was issued on August 9, 2024 by the Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Central Processing Centre. From year 2010 to 2016, our partnership firm was engaged in the marketing and trading of various pharmaceutical products. As a partnership firm, our product portfolio included tablets, capsules, oral liquids, creams, ointments, injections, lotions, oral powders and other nutraceuticals products. We procured finished goods from manufacturers and distributed them to various wholesalers and other clients throught the country.MAJOR EVENTS:2011- Started Business by starting a Partnership Firm with two Partners in name of "M/s Loreto Pharmaceutical" by Mr. Dasharathbhai Patel and Mr. Piyush Gordhanbhai Antala.2016- The Partnership Firm got converted into Private Company post conversion and receiving Certificate of Incorporation on March 23rd, 2016.2018- The Company received FDA License for manufacturing Pharma products.2019- The Company availed Kenya PPC board approval and approval from Ministry of Health - Republic of Yemen, State Good Manufacturing Practices and GLP licence from Local FDA 2020- The Company received WHO GMP certificate.2021- The Company received FDA Approval from Philippines during the tragic era of COVID-192022- Renewal of the WHO Certificates and Nigeria NAFDAC Approval2023- Retention of FDA License for manufacturing Pharma products.2025- Conversion From Private Limited into Public Limited company.

Our Company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Loreto Pharmaceutacals", pursuant to a deed of partnership dated June 2, 2010. Thereafter " M/s Loreto Pharmaceuticals" was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of "Curis Lifesciences Private Limited" and received a certificate of incorporation datedMarch 23, 2016 issued by Assistant Registrar of Companies, Gujarat. Subsequently, our Company was converted into a public limited company and the name of our Company was changed from "Curis Lifesciences Private Limited" to "Curis Lifesciences Limited" vide Special Resolution dated May 6, 2024, the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion, bearing Corporate Identification Number U24230GJ2016PLC086559, was issued on August 9, 2024 by the Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Central Processing Centre. From year 2010 to 2016, our partnership firm was engaged in the marketing and trading of various pharmaceutical products. As a partnership firm, our product portfolio included tablets, capsules, oral liquids, creams, ointments, injections, lotions, oral powders and other nutraceuticals products. We procured finished goods from manufacturers and distributed them to various wholesalers and other clients throught the country.MAJOR EVENTS:2011- Started Business by starting a Partnership Firm with two Partners in name of "M/s Loreto Pharmaceutical" by Mr. Dasharathbhai Patel and Mr. Piyush Gordhanbhai Antala.2016- The Partnership Firm got converted into Private Company post conversion and receiving Certificate of Incorporation on March 23rd, 2016.2018- The Company received FDA License for manufacturing Pharma products.2019- The Company availed Kenya PPC board approval and approval from Ministry of Health - Republic of Yemen, State Good Manufacturing Practices and GLP licence from Local FDA 2020- The Company received WHO GMP certificate.2021- The Company received FDA Approval from Philippines during the tragic era of COVID-192022- Renewal of the WHO Certificates and Nigeria NAFDAC Approval2023- Retention of FDA License for manufacturing Pharma products.2025- Conversion From Private Limited into Public Limited company.

Read More

Parent Organisation

Curis Lifesciences Ltd.

Founded

23/03/2016

Managing Director

Mr.Dharmesh Dasharathbhai Patel

NSE Symbol

CURISST

FAQ

The current price of Curis Lifesciences Ltd is

The 52-week high for Curis Lifesciences Ltd is

The market capitalization of Curis Lifesciences Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Curis Lifesciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Curis Lifesciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Curis Lifesciences Ltd shares.

The CEO of Curis Lifesciences Ltd is Mr.Dharmesh Dasharathbhai Patel, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT